Surgical outcomes of pulmonary metastasectomy for head and neck cancer in the current era of advances in chemotherapy and immunotherapy

Ochi, Takahiro; Wada, Hironobu; Nakajima, Takahiro; Tanaka, Kazuhisa; Yamamoto, Tatsuya; Sakairi, Yuichi; Suzuki, Hidemi; Yonekura, Syuji; Hanazawa, Toyoyuki; Yoshino, Ichiro

doi:10.1007/s11748-021-01611-7

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, one study designed a cabazitaxel nanoparticle carrier that can be inhaled by M2 macrophage vesicles and that, in experimental models, was able to more effectively enter tumor tissue and inhibit over 93% of LM occurrences[ 52 ]. Additionally, combining chemotherapy with targeted therapy or immunotherapy has shown promising efficacy against LM[ 53 - 55 ]. Chemotherapy is utilized in PCLM treatment, but it has limitations and challenges.…”

Section: Discussionmentioning

confidence: 99%

What should be the future direction of development in the field of prostate cancer with lung metastasis?

Huang,

Chen,

et al. 2023

World J Clin Oncol

View full text Add to dashboard Cite

BACKGROUND Since the start of the 21 st century, prostate cancer with lung metastasis (PCLM) has accumulated significant scientific research output. However, a systematic knowledge framework for PCLM is still lacking. AIM To reconstruct the global knowledge system in the field of PCLM, sort out hot research directions, and provide reference for the clinical and mechanism research of PCLM. METHODS We retrieved 280 high-quality papers from the Web of Science Core Collection and conducted a bibliometric analysis of keywords, publication volume, and citation frequency. Additionally, we selected differentially expressed genes from global high-throughput datasets and performed enrichment analysis and protein-protein interaction analysis to further summarize and explore the mechanisms of PCLM. RESULTS PCLM has received extensive attention over the past 22 years, but there is an uneven spatial distribution in PCLM research. In the clinical aspect, the treatment of PCLM is mainly based on chemotherapy and immunotherapy, while diagnosis relies on methods such as prostate-specific membrane antigen positron emission tomography/computed tomography. In the basic research aspect, the focus is on cell adhesion molecules and signal transducer and activator of transcription 3, among others. Traditional treatments, such as chemotherapy, remain the mainstay of PCLM treatment, while novel approaches such as immunotherapy have limited effectiveness in PCLM. This study reveals for the first time that pathways related to coronavirus disease 2019, cytokine-cytokine receptor interaction, and ribosome are closely associated with PCLM. CONCLUSION Future research should focus on exploring and enhancing mechanisms such as cytokine-cytokine receptor interaction and ribosome and improve existing mechanisms like cadherin binding and cell adhesion molecules.

show abstract

Section: Discussionmentioning

confidence: 99%

What should be the future direction of development in the field of prostate cancer with lung metastasis?

Huang,

Chen,

et al. 2023

World J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…However, PM can be considered for ACC considering its indolent nature. We identified 12 retrospective studies of PM in HNC which included ACC patients among other histologies (most commonly HNSCC), but did not separate survival outcomes for ACC, and thus, could not analyzed further [ 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 ]. When looking at ACC-specific post-PM survival outcomes, the results are heterogenous.…”

Section: Local Therapy For Oligometastatic Lung Diseasementioning

confidence: 99%

Approaches to the Management of Metastatic Adenoid Cystic Carcinoma

Lee

Wai

Chan

et al. 2022

Cancers

View full text Add to dashboard Cite

High rates of recurrence and distant metastasis are a foremost challenge in the management of adenoid cystic carcinoma (ACC), occurring in approximately 40% of all ACC patients. Despite the morbidity and mortality resulting from recurrent/metastatic (R/M) disease, there are no FDA-approved systemic agents for these patients. In this review, we summarize pertinent ACC pathophysiology and its implications for different systemic treatment regimens in R/M ACC. We review the evidence for the most widely used systemic agents — cytotoxic chemotherapy and tyrosine kinase inhibitors (TKIs) targeting VEGFR — in addition to immune checkpoint inhibitors and non-TKI biologic agents. Exciting emerging targets for R/M ACC, including inhibitors of Notch signaling, stemness, PRMT5, and Axl, are also discussed. Lastly, we review local therapies for small-volume lung disease in patients with oligometastatic ACC, specifically pulmonary metastasectomy and stereotactic body radiation therapy (SBRT). Future development of targeted molecular agents which exploit the underlying biology of this disease may yield novel therapeutic options to improve clinical outcomes in patients with R/M ACC.

show abstract

Current status and novel insights into the role of metastasectomy in the era of immunotherapy

Liatsou

Tsilimigras

Malandrakis

et al. 2022

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Surgical outcomes of pulmonary metastasectomy for head and neck cancer in the current era of advances in chemotherapy and immunotherapy

Cited by 3 publications

References 21 publications

What should be the future direction of development in the field of prostate cancer with lung metastasis?

What should be the future direction of development in the field of prostate cancer with lung metastasis?

Approaches to the Management of Metastatic Adenoid Cystic Carcinoma

Current status and novel insights into the role of metastasectomy in the era of immunotherapy

Contact Info

Product

Resources

About